Gemcitabine CAS 95058-81-4 Assay 98.0~102.0%
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of Gemcitabine (CAS: 95058-81-4) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Gemcitabine, Please contact: alvin@ruifuchem.com
| Chemical Name | Gemcitabine |
| Synonyms | 2'-Deoxy-2',2'-Difluorocytidine; 4-Amino-1-[3,3-Difluoro-4-Hydroxy-5-(Hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; dFDC; Gemzar (Lilly); LY-188011; dFdCyd; DDFC; 2',2'-Difluoro-2'-deoxycytidine; 2',2'-Difluorodeoxycytidine; Folfugem; GemLip; Gemcel; Gamcitabine |
| Stock Status | In Stock, Production Capacity 5 Tons |
| CAS Number | 95058-81-4 |
| Related CAS | 122111-03-9 |
| Molecular Formula | C9H11F2N3O4 |
| Molecular Weight | 263.20 g/mol |
| Melting Point | 217.0 to 222.0℃ |
| Density | 1.84±0.10 g/cm3 |
| Sensitive | Heat Sensitive |
| Water Solubility | Practically Insoluble in Water |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Items | Specifications | Results |
| Appearance | White or Almost White Crystalline Powder, Odorless | Complies |
| Cytosine | ≤0.10% | 0.002% |
| α-Isomer | ≤0.10% | 0.01% |
| Individual Impurity | ≤0.10% | 0.03% |
| Total Impurities | ≤1.00% | 0.10% |
| Water by Karl Fischer | ≤1.00% | 0.67% |
| Specific Rotation | +68.0°~+74.0° | +70.5° |
| Heavy Metals | ≤10ppm | <10ppm |
| Residue on Ignition | ≤0.10% | 0.03% |
| Assay (By HPLC) | 98.0%~102.0% | 99.9% |
| Infrared Spectrum | Consistent with Structure | Complies |
| 1H NMR Spectrum | Consistent with Structure | Complies |
| Conclusion | The product has been tested and complies with the given specifications | |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Avoid exposure to direct sunlight, moisture and excessive heat.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Risk Codes R21 - Harmful in contact with skin
R36/38 - Irritating to eyes and skin.
R46 - May cause heritable genetic damage
R62 - Possible risk of impaired fertility
R63 - Possible risk of harm to the unborn child
Safety Description S25 - Avoid contact with eyes.
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36/37 - Wear suitable protective clothing and gloves.
S53 - Avoid exposure - obtain special instructions before use.
HS Code 2934999091
Toxicity LD10 i.v. in rats: 200 mg/m2 (Abbruzzese)
Gemcitabine (CAS: 95058-81-4) is a chemotherapy medication used to treat a number of types of cancer. This includes breast cancer, non-small cell lung cancer, pancreatic cancer, bladder cancer, and biliary tract cancer. Gemcitabine is being investigated for use in esophageal cancer, and is used experimentally in lymphomas and various other tumor types. Gemcitabine is administered by the intravenous route, since it is extensively metabolized by the gastrointestinal tract.
Gemcitabine is a nucleotide analogue, which belongs to the anti-metabolic class of anticancer drugs. It mainly acts on DNA synthesis phase, that is, S phase. Under certain conditions, it can prevent G1 phase from progressing to S phase. It has the characteristics of wide anticancer spectrum, unique mechanism of action, low toxicity, no cross-resistance to other chemotherapy drugs and no superposition of toxicity. Chemicalbook, gemcitabine, is now approved for use in more than 90 countries, making it the first-line treatment for non-small cell lung cancer and the "gold standard" for pancreatic cancer.
In 1999, CFDA approved gemcitabine for the treatment of locally advanced or metastatic NSCLC, locally advanced or metastatic pancreatic cancer; In 2010, CChemicalbookFDA approved gemcitabine in combination with paclitaxel for the treatment of unresectable, locally recurrent or metastatic breast cancer that has recurred after adjuvant/neoadjuvant chemotherapy.
Gemcitabine is a broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA. This locks DNA polymerase thereby resulting in masked termination during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.
